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The interplay between the immune system and the microbiota in the human intestine
dictates states of health vs. disease. Polysaccharide capsules are critical elements of
bacteria that protect bacteria against environmental and host factors, including the host
immune system. This review summarizes the mechanisms by which polysaccharide
capsules from commensal and pathogenic bacteria in the gut microbiota modulate the
innate and adaptive immune systems in the intestine. A deeper understanding of the
roles of polysaccharide capsules in microbiota-immune interactions will provide a basis
to harness their therapeutic potential to advance human health.
Keywords: polysaccharide capsules, adaptive immunity, innate immunity, regulatory T cells, antigen processing,
intestinal microbiota
INTRODUCTION
The dynamic interactions between the gut microbiota and immune system determine whether
immune tolerance or inflammation and disease develop in the human intestine. One component of
bacteria that has been found to play an important role in regulating immune responses in the gut
are polysaccharide capsules. Polysaccharide capsules are long polysaccharide chains that form the
outermost layer of bacteria and can be several 100µm thick (1). Capsules are thought to be critical
for bacterial fitness and provide protection against many environmental and host factors, especially
since they are often the first bacterial structural encountered by the host immune system (2). The
study of bacterial capsules had a key role in the early days of molecular biology with the seminal
studies of Avery, MacLeod, and McCarty showing that DNA was the genetic material (3). They
studied two strains of Streptococcus pneumoniae, smooth (S) and rough (R), which were virulent
and avirulent, respectively. The S strain produced a capsule, whereas the R strain did not. They
were able to transform the R strain into an avirulent S strain using DNA from the S strain, thereby
proving that DNA was the genetic material (3).
One striking feature of the capsules in general is their chemical and structural diversity within
a given bacterial species. They can be composed of different monosaccharides, which can also vary
in their stereoisomers (D or L), number of carbon molecules forming the sugar ring structure
(furanose or pyranose), and configuration of the anomeric center of each sugar (Cα or Cβ) (4).
These polysaccharides can be further diversified by branching and glycosidic linkage patterns (α
or β), covalent coupling to other biological molecules such as proteins and lipids, and forming
secondary structures (5). This astronomical diversity likely equips polysaccharide capsules with
many different functions that enhance bacterial fitness.
Polysaccharide capsules have been shown to enhance bacterial survival in the gut by multiple
mechanisms. Capsule composition varies with diet and different capsules may provide optimal
access to various nutrients and more efficient use of the bacterial cell’s resources (5). Another role
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of polysaccharide capsules in the gut microbiota is exclusion
of pathogens as capsule expression has been shown to alter
disease symptoms as well as bacterial attachment to host cells
and thus bacterial abundance (5). Capsules can be degraded by
other microbes, which can be either beneficial or detrimental
to the bacteria. In mutualistic relationships, they can be used
as a nutrient source for neighboring bacteria. However, capsules
can also be degraded by competing bacteria, reducing bacterial
fitness. Capsules have also been shown to provide protection
against bacteriophages (5). In addition, polysaccharide capsules
can alter immune responses to bacteria. Interestingly, evenminor
differences between capsules can completely alter the immune
response as each is recognized as immunologically distinct (4).
Some bacteria, especially the Bacteroides species, express
polysaccharide capsules that are phase variant and are able
to switch between different capsules (6). This phase variance
arises because each polysaccharide can regulate its expression
using a reversible on-off phenotype, which is controlled by
inversions of the DNA promoter regions that lie upstream of
their polysaccharide biosynthesis loci (7). These inversions place
the promoters in either the correct or incorrect orientation
for transcription of the downstream polysaccharide biosynthesis
genes. Phase variation is thought to equip bacteria to adapt and
survive in different niches in the gut and may be especially
advantageous in the face of immune pressure by enabling bacteria
to alter their surface antigenicity (5).
The two main types of polysaccharide capsules are
exopolysaccharides (EPSs) and capsular polysaccharides
(CPSs). EPSs contain glycans that are loosely associated with
microbial cell surfaces, while CPSs are composed of glycans that
are firmly attached to the cell surface (5). However, determining
whether or not glycans are attached to the cell surface is difficult,
so these terms are often used interchangeably. In this review,
we will use the term microbially produced glycans (MPGs) to
encompass both CPSs and EPSs (5). MPGs have been found in a
variety of Gram-negative and Gram-positive bacteria including
Escherichia coli, Neisseria meningitides, Haemophilus influenza,
Staphylococcus aureus, and Streptococcus pneumoniae and are
critical for serological classification and vaccine development
(2). Although the roles of MPGs in the gut microbiota are
less understood, there have been many recent advances in
understanding the interplay between bacterial MPGs and the
host immune system in the intestine. Here we review the
current literature on the immunomodulatory roles of MPGs in
the intestine on both innate and adaptive immune responses.
A summary of the effects of different MPSs, their capsule
composition, immune cell target, and mechanisms of action are
detailed in Table 1.
MPGS MODULATE INNATE IMMUNE
RESPONSES IN THE INTESTINE
The innate immune system is the first line of defense against
many pathogens, and MPGs have been shown to be critical for
regulating innate immune responses in the gut. One mechanism
the innate system uses to combat bacterial infection is the
production of antimicrobial peptides such as defensins and
cathelicidins by the intestinal epithelium. MPGS can block the
bactericidal activity of antimicrobial factors, enabling bacteria
to evade these innate immune responses. For example, wild-
type (WT) enteropathogenic Escherichia coli (EPEC) was more
resistant to human α-defensin 5 (HD-5) than an unencapsulated
EPEC mutant (35). An unencapsulated EPEC strain could be
protected from HD-5 killing by the addition of exogenous EPEC
polysaccharide, suggesting that the EPEC capsule likely binds
HD-5 and traps it before it reaches the bacterial membrane (35).
Similarly, EPS from the probiotic Lactobacillus rhamnosus GG
(LGG) protected LGG from the LL-37/human cationic protein
18 from the cathelicidin family (42). Viability of an EPS− LGG
strain was reduced in the presence of LL-37, while an EPS+ LGG
strain had no change in viability. In addition, growing LGG in the
presence of subinhibitory concentrations of LL-37 induced EPS
expression, further demonstrating that EPSs protect microbes
from antimicrobial peptides (42).
Another method the innate immune system uses to recognize
and destroy bacteria is complement. MPGs can block the
deposition of complement on bacterial surfaces, which prevents
bacteria from being targeted for destruction by the immune
system. EPS from LGG also protected against complement-
mediated lysis as an EPS− LGG strain, but not an EPS+
LGG strain, had a reduction in viability after incubation with
normal human serum (42). Although WT Salmonella enterica
serovar Typhimurium was resistant to killing by normal
human serum, an EPS− strain had increased serum sensitivity
as well as faster C3 surface deposition (46). Similarly, an
unencapsulated strain of Shigella sonnei was more vulnerable
to complement than WT and also had a reduced ability to
disseminate peripherally (50). Vibrio cholera’s CPS also protects
against complement-mediated bacteriolysis and strains isolated
from patients that contained less capsular material were more
susceptible to the bactericidal activity of serum (53, 54). The
CPS of Campylobacter jejuni blocks antibody binding and
activation of complement and non-stoichiometric O-methyl
phosphoramidate (MeOPN) modifications at the 4 position of
galactose has been shown to be the most critical to complement
resistance (33). An acapsular strain of the Gram-negative
symbiont Bacteroides thetaiotaomicron, which lacks expression
of all B. thetaiotaomicron CPSs, also had a decrease in survival
after treatment with normal human serum compared to WT,
further suggesting that CPSs can enable bacteria to circumvent
complement (25). Interestingly, B. thetaiotaomicron strains that
singly expressed different CPSs had varying susceptibilities to
normal human serum as CPS2, CPS4, CPS5, CPS6, and WT
were more resistant to complement than CPS1, CPS3, CPS7, and
CPS8 (25). These findings demonstrate that MPGs can protect
bacteria by inhibiting complement deposition on the surface of
bacteria, which prevents complement-mediated lysis as well as
uptake by phagocytic cells.
MPGs can also directly block bacterial uptake by innate
immune cells, which prevents phagocytic cells from killing
bacteria and antigen presenting cells from presenting antigenic
peptides on the surfaces that may activate the adaptive immune
system. For example, B. thetaiotaomicron with anti-stimulatory

















































Bacillus subtilis Gram + Commensal EPS Mannose (88%), glucose (11.9%),
N-acetylglucosamine (0.1%); Primary linkages:
2,6-mannose (31.8%), terminal mannose
(29.9%), 3-mannose (15%), 2-mannose (4.7%),
6-mannose (4.7%), 6-glucose (3.7%), and
terminal glucose (3.5%)
Macrophages Signals through TLR4/MyD88 pathway to
induce M2 macrophages, which inhibit CD4+ T
cells via TGF-β and CD8+ T cells via TGF-β







Gram − Commensal CPS Acetamido-amino-2,4,6-trideoxygalactose
(AATGal) amino sugar; zwitterionic






Bacteroides fragilis Gram − Commensal CPS:
PSA
Tetrasaccharide repeating unit containing
4,6-pyruvate attached to a d-galactopyranose,
2,4-dideoxy-4-amino-d-FucNAc,
d-N-acetylgalactosamine, and
d-galactofuranose with one positively charged
free amine and one negatively charged
carboxylate; zwitterionic
Dendritic cells Enhances antigen presentation by upregulating
MHC II, CD80, and CD86; phagocytosed by
APCs and displayed on MHC II to activate
CD4+ T cells in a TLR2-dependent manner;
corrects CD4+ T cell deficiencies and TH1/TH2
imbalance in germ-free mice by upregulating
the production of IFN-γ+ TH1T cells through
CD11c+ DCs and the IL-12/STAT4 pathway;
represses TH17 responses; induces IL-10
producing FoxP3+ Tregs in a TLR2-dependent
manner; protects against TNBS-induced colitis







Gram − Commensal CPS:
CPS 1-8
CPS1: 22% N-acetyl-glucosamine, 33%
glucose, 9% mannose, 36% galacturonic acid
CPS2: 8% N-acetyl-glucosamine, 85%
glucose, 7% mannose
CPS3: 18% N-acetyl-glucosamine, 42%
glucose, 34% mannose, 6% galacturonic acid
CPS4: 61% N-acetyl-glucosamine, 21%
glucose, 18% galacturonic acid
CPS5: 10% N-acetyl-galactosamine, 7%
N-acetyl-glucosamine, 27% galactose, 49%
glucose, 8% mannose
CPS6: 23% N-acetyl-galactosamine, 8%
N-acetyl-glucosamine, 37% galactose, 23%
glucose, 6% mannose, 3% glucuronic acid
CPS8: 19% N-acetyl-glucosamine, 2%





CPS2, CPS4, CPS5, CPS6, and WT are more
resistant to complement; CPS1-6 inhibit APC
phagocytosis and antigen presentation likely
due to increased capsule thickness and
decrease IL-6 and TNF-α production in a
MyD88-dependent manner; CPS5 promotes
evasion of IgA responses; CPS1 represses
polyclonal and antigen-specific T cell activation











Gram + Commensal CPS Mixture of four neutrally charged cell surface
β-glucan/galactan (CSGG) polysaccharides:
β-(1 → 6)-glucan, β-(1 → 4)-galactan, β-(1
→ 6)-galactan, β-galactofuranan and starch
Dendritic cells induces IL-10 and FoxP3+ Tregs through
TLR2-mediated mechanism on DCs;




































































































Gram + Commensal EPS Glucose, galactose and/or the N-acetylated
versions of these two sugars
B cells Decreases numbers of B cells and
antigen-specific total Ig, IgG3, IgG1, IgG2a,
and fecal IgA titers; elicits weaker antibody
responses by masking surface antigens





Gram + Commensal EPS Branched hexasaccharide repeating unit with
two galactoses, two glucoses, galacturonic





Decrease IFN-γ, IL-12, TNF-α, IL-17, IL-6
production; prevents phagocytosis; represses
TH17 recruitment; protects against T cell







Gram − Pathogen CPS Heptoses in unusual configurations (e.g., ido,
gulo, and altro) and non-stoichiometric
modifications on the sugars, including





Blocks antibody binding and activation of
complement; decreases activation of TLR4 and
production of IL-1β, IFN-γ, and IL-6
Complement evasion (33, 34)
Enteropathogenic
Escherichia coli
Gram − Pathogen CPS: Gp
4
capsule
Linear tetrasaccharide made of L-fucose,
D-galactose and two N-acetyl-galactosamines
Human
α-defensin 5
Uses its anionic charges to prevent cationic








Gram + Commensal EPS Unknown Dendritic cells Decreases IL-12p70 and IFN-γ and increases
IL-10 secretion through TLR2 signaling by







Gram − Pathobiont CPS α-mannose and α-glucose sugars Macrophages Signals through TLR2/MyD88 pathway to






Gram + Commensal EPS MMMP1: main chain of 1,6-β-D-Galfs with
non-stoichiometric 2-O-glucosylation.
MMMP2: a repeat unit → 3)-β-D-Glcp-(1 →
3)-β-D-Galf-(1 →
6)-[2-α-D-Glcp]β-D-Galf-(1→





Gram + Commensal EPS EPS-1: branched dextran with every backbone
residue substituted with a 2-linked glucose unit
and polysaccharides partially occupied by




polysaccharides partially occupied by single
O-acetyl group
Unknown Masks cell surface epitopes from antibodies Masks surface antigens (39)
Lactobacillus
kefiranofacien











Resists cationic LL-37/human cationic protein
18 by forming protective shield with long and
neutral EPS; protects against complement





































































































Gram + Commensal EPS Glucose and fructose Unknown Induces IgA production, retinoic acid synthase,





















Decreases C3 surface deposition; decreases





Salmonella Typhi Gram − Pathogen CPS: Vi Homopolymer of (1,4)-2-acetamido-3-O-
acetyl-2-deoxy-α-D-galacturonic
acid
T cells Represses T cell responses by binding to T
cells through the prohibitin complex and
inhibiting IL-2 secretion; prevents C3









High molecular weight polysaccharide
containing FucNAc4N and L-AltNAcA residues
in 1:1 ratio
Complement Resists direct complement-mediated killing Complement evasion (50)
Streptococcus
thermophiles
Gram + Commensal EPS 12.9% rhamnose, 26% glucose, 60.9%
galactose, 0.25% mannose
Unknown Decreases IFN-γ, IL-6, and TNF-α production Cytokine production (51)
Vibrio cholerae Gram − Pathogen CPS (O-
antigen
CPS)
Polymerized O-antigen subunits composed of
N-acetylglucosamine, N-acetyl-quinovosamine,
galacturonic acid, galactose andcolitose
Complement Resists complement-mediated bacteriolysis
likely by promoting binding of negative
regulatory proteins and inhibiting efficient
complement fixation at the bacterial surface
Complement evasion (52, 53)













































Hsieh and Allen Immunomodulatory Roles of Bacterial Capsules
CPSs such as CPS1 are poorly uptaken by bone-marrow
macrophages (BMDM) and splenic CD11c+ dendritic cells
(DCs) (24). In contrast, B. thetaiotaomicron expressing pro-
stimulatory CPSs such as CPS8 or Acap are readily phagocytosed.
These differences in phagocytosis may be partly explained by the
thicknesses of the B. thetaiotaomicron CPSs as anti-stimulatory
CPSs tended to be thicker than pro-stimulatory CPSs. In support
of these findings, B. thetaiotaomicron expressing anti-stimulatory
CPSs were cleared less effectively from the peritoneal cavity
than B. thetaiotaomicron expressing pro-stimulatory CPSs in
vivo, likely because anti-stimulatory CPSs inhibited uptake by
peritoneal innate immune cells (24). In addition, innate immune
phagocytes cultured with B. thetaiotaomicron expressing anti-
stimulatory CPSs were poor antigen presenters to the adaptive
immune system. Bifidobacterium longum’s EPS also inhibited
macrophage phagocytosis (32). In contrast, other MPGs can
promote the maturation of innate immune cells so that they
serve as better antigen presenting cells (APCs) to the adaptive
immune system. For example, the polysaccharide A capsule
(PSA) expressed on Bacteroides fragilis upregulates MHC II
expression on CD11c+ dendritic cells as well as the co-
stimulatory molecules CD80 and CD86, which enhances antigen
presentation (18).
Innate immune responses to bacteria can also be thwarted
by MPGs that promote immune tolerance by inducing innate
immune cells to release anti-inflammatory cytokines in the
intestine. A large soluble polysaccharide released by the Gram-
negative Helicobacter hepaticus induced an anti-inflammatory
M2 gene signature as well as IL-10 production in intestinal
macrophages through TLR2, mitogen and stress-activated
protein kinase (MSK), and cyclic AMP response-element binding
protein (CREB) (37). Similarly, the EPS from the Gram-
positive probiotic Bacillus subtilis elicited anti-inflammatory
M2 macrophages through TLR4, which was required for EPS-
mediated protection from Citrobacter rodentium-induced colitis
(8, 9) and limited inflammation during Staphylococcus aureus
infection (55).
Other MPGs protect bacteria from innate immune responses
by reducing the production of pro-inflammatory cytokines by
innate immune cells. Anti-stimulatory CPSs expressed on B.
thetaiotaomicron decreased the levels of the pro-inflammatory
cytokines IL-6 and TNF-α produced by macrophages and
dendritic cells (DCs) in the presence of B. thetaiotaomicron
(24). Neutrophils, macrophages, and NK cells each produced less
IFN-γ, IL-12, and TNF-α in mice treated with EPS+ vs. EPS−
Bifidobacterium breve (B. breve) (28). EPS from Bifidobacterium
longum also induced lower levels of IL-12p70, IFN-γ, and IL-
17 in human peripheral blood mononuclear cells and IL-17,
IL-6, and TNF-α in human monocyte-derived dendritic cells
compared to an EPS− B. longum strain (31). In support of
these findings, adding isolated EPS to PBMC cultures with
EPS− B. longum reduced the secretion of IL-12p70 and IFN-
γ (31). Neutrally charged EPS from the putative probiotic
Streptococcus thermophiles also decreased the production of
the pro-inflammatory cytokines IFN-γ, IL-6, and TNF-α in
DSS-induced colitis (51). The production of TNF-α and IL-
8 production by human monocyte-derived macrophages was
reduced in the presence of an EPS+ Pediococcus parvulus
strain compared to an EPS− strain (44). Campylobacter jejuni’s
CPS decreases activation of TLR4 and production of pro-
inflammatory IL-1β, IFN-γ, and IL-6 (33). Expression of
Salmonella’s Vi capsular polysaccharide led to a decline in
IL-6 and TNF-α secretion by BMDM in a TLR-dependent
manner (47). In addition, an extracellular polymeric matrix
from Faecalibacterium prausnitzii reduced the secretion of pro-
inflammatory IL-12p70 in a TLR2-dependent manner in human
monocyte-derived DCs cultured with Lactobacillus plantarum
compared to L. plantarum alone (36). These results demonstrate
that the gut microbiota also uses MPGs to inhibit innate immune
responses by decreasing the production of pro-inflammatory
cytokines and increasing the production of anti-inflammatory
cytokines by innate immune cells. This induction of innate
immune tolerance by MPGs may represent one way innate
immune cells are able to distinguish between pathogens and
commensal bacteria, although this mechanism can also be co-
opted by pathogens to evade the innate immune system.
MPGS MODULATE ADAPTIVE IMMUNE
RESPONSES IN THE INTESTINE
The host immune system also consists of adaptive immunity,
especially B and T cells, which protect the intestine from
bacterial pathogens in an antigen-specific manner and induce
immunological memory that leads to enhanced immune
responses to consequent encounters with pathogens. Bacteria
also encounter the adaptive immune system in the intestine,
and the ability of MPGs to evade adaptive immune responses is
crucial to their fitness and survival in the gut. One mechanism
MPGs use to modulate the adaptive immune system is regulating
the interactions between B cells, antibodies, and bacteria. Many
MPGs inhibit B cell and antibody responses to bacteria. For
example, EPS+ B. breve-treatedmice had decreased numbers of B
cells as well as lower antigen-specific total Ig, IgG3, IgG1, IgG2a,
and fecal IgA titers (28). EPS+ B. breve persisted longer than
EPS− B. breve in WT mice, but this difference was abolished in
B cell-deficient mice, suggesting that EPS on B. breve modulates
B cells and plays a role in evading adaptive immune responses.
In addition, EPS+ B. breve weakly agglutinated with anti-EPS
serum, while EPS− B. breve strongly agglutinated with serum
from EPS−-treated mice but not anti-EPS serum, demonstrating
that MPGs can mask surface antigens from detection and
thereby elicit weaker antibody responses (28). EPS from the
potential probiotic Lactobacillus johnsonii also protected cell
surface epitopes from exposure to antibodies as an EPS− strain
of the potential probiotic Lactobacillus johnsonii bound to more
polyclonal antibody raised against WT L. johnsonii than an
EPS+ strain. A mutant that overexpressed L. johnsonii EPS
had similar levels of bound antibody compared to wild type,
indicating that the L. johnsonii EPS itself is poorly recognized
by the immune system (39). In germ-free mice that were
colonized with all 8 single CPS-expressing B. thetaiotaomicron
strains, higher levels of IgA production correlated with increased
abundance of the CPS5-expressing strain, suggesting that some
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CPSs such as CPS5 may promote evasion of IgA responses (25).
In contrast, other MPGs promote the production of antibodies
as EPSs from the probiotic lactic acid bacteria Lactobacillus
kefiranofaciens, Leuconostoc mesenteroides, and Lactobacillus
fermentum induced IgA production in the intestine, which may
enhance the protective nature of intestinal barrier (38, 40, 43).
Thus, depending on the MPG, MPGs can either inhibit or bolster
B cell and antibody responses in the intestine.
Many MPGs can also modulate T cell responses in the
intestine, including by functioning as T cell antigens and
by regulating both polyclonal and antigen-specific T cells.
Most polysaccharides are classically considered to be T cell-
independent antigens that do not induce the activation of
helper T cells that stimulate Ig class switching in B cells
or immunologic memory (56). Instead, polysaccharides must
be coupled to protein carriers in order to enlist T cell help
and induce IgG antibodies and memory B cells such as in
vaccines (6). Although carbohydrates are not usually T cell
antigens, zwitterionic polysaccharides (ZPSs), which contain
both a positive and negative charge, are unique MPGs that have
been shown to regulate T cells by directly acting as a T cell
antigen. The best studied zwitterionic MPG is the B. fragilis PSA.
Although PSA is a carbohydrate, PSA can be presented by APCs
to activate T cells (11, 12). PSA is taken-up into APC endosomes,
processed by inducing nitric oxide production through TLR2,
and is displayed on major histocompatibility complex (MHC)
II to activate CD4+ T cells in mice (14, 16, 17, 23). In human
dendritic cells (DCs), the C-type lectin dendritic cell-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) is the main receptor for PSA (57). PSA’s ability to directly
stimulate TLR2 has recently come under debate as PSA is
not a typical TLR2-stimulating molecular structure and one
study suggests that the lipoproteins in B. fragilis glycoconjugate
fractions are responsible for stimulating TLR2, not PSA (58). PSA
is currently the only CPS that has been shown to function as an
antigen and is directly presented to T cells.
MPGs have also been shown to be critical for maturation
of the host immune system, especially the development of T
cells. Although germ-free mice that lack the bacterial microflora
are known to exhibit immunological defects, B. fragilis PSA
was sufficient to correct these T cell deficiencies (18). Mono-
colonizing germ-free mice with WT B. fragilis or purified PSA,
but not PSA-deficient B. fragilis, corrected the CD4+ T cell
deficiencies in germ-free mice. Although PSA had no effect
on the proportions of CD8+ T cells or CD19+ B cells, PSA
also corrected the TH1/TH2 imbalance in germ-free mice by
upregulating the production of IFN-γ+ TH1 T cells through
CD11c+ DCs and the IL-12/STAT4 pathway (18).
MPGs can also modulate the activation of polyclonal T cell
responses, especially by directing T cell differentiation. Most
T cell effects of MPGs that have been studied induce a state
of immune tolerance by suppressing T cell responses. In the
Powrie model of colitis, EPS+ B. longum induced fewer IL-
17A+ lymphocytes and protected against colitis compared to
EPS− B. longum (31). Salmonella Typhi capsular polysaccharide
Vi repressed T cell responses by binding to T cells through
the prohibitin complex and inhibiting IL-2 secretion (48). B.
thetaiotaomicron expressing anti-stimulatory CPSs were also
found to activate polyclonal T cells in germ-free mice more
weakly than B. thetaiotaomicron expressing pro-stimulatory CPSs
(24). In addition, B. fragilis PSA repressed TH17 cell responses,
which is required for B. fragilis colonization, as B. fragilis
lacking PSA was unable to restrain TH17 cell responses through
TLR2 in contrast to WT B. fragilis (21). Many MPGs also
direct polyclonal T cells to differentiate into regulatory T cells
(Tregs) that often suppress effector T cells as well as intestinal
inflammation. B. fragilis PSA induces the differentiation of
IL-10 producing FoxP3+ Tregs in mice in a TLR2-dependent
manner, which can protect against TNBS-induced colitis and
experimental colitis induced by Helicobacter hepaticus (15, 19,
20, 22). PSA can also generate human IL-10 producing Tregs
in vitro (22, 59). Additionally, zwitterionic MPGs on other
bacteria can stimulate more IL-10 and higher proportions of
CD4+ FoxP3+ regulatory T cells than non-ZPS strains (10).
Non-ZPSs can also promote the production of Tregs as neutrally
charged cell surface β-glucan/galactan (CSGG) polysaccharides
from Bifidobacterium bifidum induced Treg cells in the intestine
and suppressed inflammation in a T cell transfer model of
colitis (27). Interestingly, MPGs on outer membrane vesicles
(OMVs), which are released by many Gram-negative bacteria,
can also regulate T cell responses similarly to MPGs on whole
bacteria. B. thetaiotaomicron OMVs that singly expressed anti-
stimulatory CPSs poorly stimulated T cells compared to B.
thetaiotaomicron OMVs that singly expressed pro-stimulatory
CPSs just like CPSs on whole B. thetaiotaomicron (24). B. fragilis
OMVs that contained PSA induced more IL-10 production and
CD4+ FoxP3+Tregs compared toOMVs that lacked PSA, which
also corresponded with the PSA effects observed on whole B.
fragilis (60).
In addition to modulating polyclonal T cell responses, MPGs
can regulate T cell responses to dominant antigens. Using
a B. thetaiotaomicron-specific CD4+ T cell called BθOM, B.
thetaiotaomicron expressing anti-stimulatory CPSs was found
to weakly activated BθOM T cells while B. thetaiotaomicron
expressing pro-stimulatory CPSs strongly activate BθOM T cells
in vitro and in vivo (24). CPSs on B. thetaiotaomicron also
directed the differentiation of antigen-specific T cells as BθOM
T cells in the colon differentiated into more IFN-γ+ IL-17A+
T cells in the presence of B. thetaiotaomicron containing pro-
stimulatory CPSs than anti-stimulatory CPSs (24). These findings
demonstrate that by altering MPGs, bacteria can also modulate
adaptive immune responses to their dominant antigens.
DISCUSSION
MPGs play critical roles in regulating the immune responses
to the microbiota in the intestine. Many MPGs enable
bacteria to evade innate and adaptive immune responses by
forming protecting shields around bacteria. For example, MPGs
can protect bacteria from antimicrobial factors, complement
deposition, and phagocytosis by innate immune cells. MPGs
also promote immune tolerance by inducing the innate immune
system to produce more anti-inflammatory cytokines or fewer
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pro-inflammatory cytokines as well as maturation of innate
immune cells tomake them better APCs for the adaptive immune
system. Adaptive immune responses can also be modulated
by MPGs as MPGs can block B cell and antibody responses,
especially by masking surface antigens. In addition, MPGs, even
on OMVs, can regulate T cell responses by directly serving as the
T cell antigen or by controlling the activation and differentiation
of polyclonal and antigen-specific T cells.
MPGs are critical components of the gut microbiota,
and deciphering the roles of MPGs in microbiota-immune
interactions in the intestine is crucial for improving human
health. Despite the progress in understanding how MPGs
modulate immune responses to intestinal bacteria, many
immunoregulatory functions of MPGs are still poorly
understood. For example, why some non-zwitterionic MPGs
are anti-stimulatory whereas others are pro-stimulatory is
not known. In addition, bacteriophages can regulate the
immune system (61) and MPG-specific bacteriophages have
been identified (62), but the interactions between MPG-
specific bacteriophages, MPGs, and the immune system
remain to be elucidated. Progress in this area has been
hampered by the complex chemical structures of MPGs
and additional analyses are required to decipher the MPG
structures and the mechanisms by which they regulate
the immune system. Given the astronomical diversity of
MPGs, MPGS likely have many more roles in modulating
immune responses that have yet to be discovered. More
studies are needed expand the known lexicon of bacterial
polysaccharide-immune system interactions, and they
may even lead to the discovery of new, bioactive CPS for
potential use as therapeutics to improve human health.
(13, 26, 29, 30, 32, 34, 41, 45, 49, 53).
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